Pulmonary hypertension in patients with interstitial lung disease

Karampitsakos, Theodoros; Tzouvelekis, Argyrios; Chrysikos, Serafeim; Bouros, Demosthenes; Tsangaris, Iraklis; Fares, Wassim H.

doi:10.1016/j.pupt.2018.03.002

Cited by 24 publications

(16 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, most studies show this finding. [33,35,36] By contrast Oda et al, [37] in a recent study in Japan similar in design to ours, did not observe that pulmonary hypertension influenced the prognosis of hospitalized patients with idiopathic pulmonary fibrosis.…”

Section: Discussioncontrasting

confidence: 52%

See 1 more Smart Citation

Characteristics and outcomes of patients hospitalized with interstitial lung diseases in Spain, 2014 to 2015

Pedraza-Serrano¹,

Jiménez-García²,

López‐de‐Andrés³

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 52%

“…The prevalence of pulmonary hypertension found in our study in patients with sarcoidosis was 6.1%, being in the range of the prevalence described by other authors, which is between 5% and 15%. [35]…”

Section: Discussionmentioning

confidence: 99%

Characteristics and outcomes of patients hospitalized with interstitial lung diseases in Spain, 2014 to 2015

Pedraza-Serrano¹,

Jiménez-García²,

López‐de‐Andrés³

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…Importantly, IPF is an age-related disease and thus presents with major comorbidities that significantly impact survival and quality of life (7)(8)(9). Besides the traditionally recognized comorbidities of lung cancer, pulmonary hypertension and gastroesophageal reflux disease (7,(10)(11)(12)(13), conditions related to the psychological impact of the disease have recently gained much of attention.…”

Section: Introductionmentioning

confidence: 99%

Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…IPF primarily affects older adults and causes symptoms, such as shortness of breath (dyspnea), coughing, limitations on physical activity,10,11 and reduced health-related quality of life 10,12. Complications include pulmonary hypertension, heart failure, lung cancer, and respiratory failure, which serves as the most common cause of premature death 8,13,14. The course and severity of symptoms are highly variable, but prognosis is typically poor, with median survival 3–5 years after diagnosis 8,15,16.…”

Section: Introductionmentioning

confidence: 99%

<p>Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis</p>

Hollin¹,

Dimmock²,

Bridges³

et al. 2019

PPA

View full text Add to dashboard Cite

Purpose: Rare diseases present challenges for accessing patient populations to conduct surveys. Clinical Data Research Networks (CDRNs) offer an opportunity to overcome those challenges by providing infrastructure for accessing patients and sharing data. This study aims to demonstrate the feasibility of collecting patient preference information for a rare disease in a CDRN, using idiopathic pulmonary fibrosis as proof of concept. Patients and methods: Utilizing a cohort of idiopathic pulmonary fibrosis (IPF) patients across a CDRN, a discrete choice experiment was administered via electronic and paper methods to collect patient preference information about benefits and risks of two therapeutic options. Survey data were augmented with data from electronic health records and patient-reported outcome surveys. Results: Thirty-three patients completed the preference experiment. The amount of choice attributable to a benefit of slowing of decline in lung function was 36%. Improving efficacy in terms of lung function was 2.16 times as important as improving efficacy in terms of shortness of breath. In terms of side effects, decreasing risk of gastrointestinal problems was 2.6 times as important as decreasing risk of sun sensitivity and 2.4 times as important as decreasing risk of liver injury. In terms of benefit-risk trade-offs, improving efficacy in terms of lung function was 1.6 times as important as decreasing risk of gastrointestinal problems. Conclusion: This study used IPF as a proof of concept to demonstrate the feasibility of collecting patient preference information in a CDRN. The network was advantageous to the study of patient preferences. Future research should continue to explore pathways for the collection and use of patient preference information across networks. The power of consolidated collection efforts may lead to the ability to use preference data to inform decision-making at the regional, specialty, or individual encounter level.

show abstract

Pulmonary hypertension in patients with interstitial lung disease

Cited by 24 publications

References 160 publications

Characteristics and outcomes of patients hospitalized with interstitial lung diseases in Spain, 2014 to 2015

Characteristics and outcomes of patients hospitalized with interstitial lung diseases in Spain, 2014 to 2015

Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis

<p>Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis</p>

Contact Info

Product

Resources

About